Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

A novel experimental model of cervical spondylotic myelopathy (CSM) to facilitate translational research.

Karadimas SK, Moon ES, Yu WR, Satkunendrarajah K, Kallitsis JK, Gatzounis G, Fehlings MG.

Neurobiol Dis. 2013 Jun;54:43-58. doi: 10.1016/j.nbd.2013.02.013. Epub 2013 Mar 4.

PMID:
23466695
2.

Development and characterization of a novel rat model of cervical spondylotic myelopathy: the impact of chronic cord compression on clinical, neuroanatomical, and neurophysiological outcomes.

Lee J, Satkunendrarajah K, Fehlings MG.

J Neurotrauma. 2012 Mar 20;29(5):1012-27. doi: 10.1089/neu.2010.1709. Epub 2011 Aug 29.

PMID:
21561323
3.

Cervical spondylotic myelopathy: the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder.

Kalsi-Ryan S, Karadimas SK, Fehlings MG.

Neuroscientist. 2013 Aug;19(4):409-21. doi: 10.1177/1073858412467377. Epub 2012 Nov 30. Review.

PMID:
23204243
4.

Immunohistochemical profile of NF-κB/p50, NF-κB/p65, MMP-9, MMP-2, and u-PA in experimental cervical spondylotic myelopathy.

Karadimas SK, Klironomos G, Papachristou DJ, Papanikolaou S, Papadaki E, Gatzounis G.

Spine (Phila Pa 1976). 2013 Jan 1;38(1):4-10. doi: 10.1097/BRS.0b013e318261ea6f.

PMID:
22673181
5.

Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy.

Moon ES, Karadimas SK, Yu WR, Austin JW, Fehlings MG.

Neurobiol Dis. 2014 Feb;62:394-406. doi: 10.1016/j.nbd.2013.10.020. Epub 2013 Oct 29.

PMID:
24184328
6.

Molecular mechanisms of spinal cord dysfunction and cell death in the spinal hyperostotic mouse: implications for the pathophysiology of human cervical spondylotic myelopathy.

Yu WR, Baptiste DC, Liu T, Odrobina E, Stanisz GJ, Fehlings MG.

Neurobiol Dis. 2009 Feb;33(2):149-63. doi: 10.1016/j.nbd.2008.09.024. Epub 2008 Oct 18.

PMID:
19006686
7.

Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy.

Yu WR, Liu T, Kiehl TR, Fehlings MG.

Brain. 2011 May;134(Pt 5):1277-92. doi: 10.1093/brain/awr054. Epub 2011 Apr 13.

9.

Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.

Yamamoto S, Kurokawa R, Kim P.

J Neurosurg Spine. 2014 Jan;20(1):93-101. doi: 10.3171/2013.9.SPINE121136. Epub 2013 Nov 8.

PMID:
24206033
10.

New experimental rabbit animal model for cervical spondylotic myelopathy.

Klironomos G, Karadimas S, Mavrakis A, Mirilas P, Savvas I, Papadaki E, Papachristou DJ, Gatzounis G.

Spinal Cord. 2011 Nov;49(11):1097-102. doi: 10.1038/sc.2011.71. Epub 2011 Jul 26.

PMID:
21788956
11.

Preoperative evaluation of the cervical spondylotic myelopathy with flexion-extension magnetic resonance imaging: about a prospective study of fifty patients.

Zhang L, Zeitoun D, Rangel A, Lazennec JY, Catonné Y, Pascal-Moussellard H.

Spine (Phila Pa 1976). 2011 Aug 1;36(17):E1134-9. doi: 10.1097/BRS.0b013e3181f822c7.

PMID:
21785299
12.

Pathophysiology and natural history of cervical spondylotic myelopathy.

Karadimas SK, Erwin WM, Ely CG, Dettori JR, Fehlings MG.

Spine (Phila Pa 1976). 2013 Oct 15;38(22 Suppl 1):S21-36. doi: 10.1097/BRS.0b013e3182a7f2c3. Review.

PMID:
23963004
13.

Increased spinal cord movements in cervical spondylotic myelopathy.

Vavasour IM, Meyers SM, MacMillan EL, Mädler B, Li DK, Rauscher A, Vertinsky T, Venu V, MacKay AL, Curt A.

Spine J. 2014 Oct 1;14(10):2344-54. doi: 10.1016/j.spinee.2014.01.036. Epub 2014 Jan 23.

PMID:
24462810
14.
15.

Limaprost alfadex, a prostaglandin E1 derivative, prevents deterioration of forced exercise capability in rats with chronic compression of the spinal cord.

Kurokawa R, Nagayama E, Murata H, Kim P.

Spine (Phila Pa 1976). 2011 May 15;36(11):865-9. doi: 10.1097/BRS.0b013e3181e878a1.

PMID:
21192291
16.
17.

Pathobiology of cervical spondylotic myelopathy.

Karadimas SK, Gatzounis G, Fehlings MG.

Eur Spine J. 2015 Apr;24 Suppl 2:132-8. doi: 10.1007/s00586-014-3264-4. Epub 2014 Mar 14. Review.

PMID:
24626958
18.

Prognostic factors for deterioration of patients with cervical spondylotic myelopathy after nonsurgical treatment.

Shimomura T, Sumi M, Nishida K, Maeno K, Tadokoro K, Miyamoto H, Kurosaka M, Doita M.

Spine (Phila Pa 1976). 2007 Oct 15;32(22):2474-9.

PMID:
18090088
19.

[Experimental study of cervical spondylotic myelopathy--spinal cord blood flow in cervical canal stenosis (author's transl)].

Nakamura K, Machida H, Tanaka H, Kobayashi M, Hoshino Y, Iizuka T, Kurokawa T.

Nihon Seikeigeka Gakkai Zasshi. 1981 Aug;55(8):747-54. Japanese.

PMID:
7310208
20.

Magnetic resonance T2 image signal intensity ratio and clinical manifestation predict prognosis after surgical intervention for cervical spondylotic myelopathy.

Zhang YZ, Shen Y, Wang LF, Ding WY, Xu JX, He J.

Spine (Phila Pa 1976). 2010 May 1;35(10):E396-9. doi: 10.1097/BRS.0b013e3181c6dbc4.

PMID:
20393392
Items per page

Supplemental Content

Write to the Help Desk